Processa Pharmaceuticals, Inc. Share Price & Technical Analysis
PCSA · $2.65 (+5.58%)
Healthcare / Biotechnology
$2.65
+5.58%
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cel…
Price chart
Seasonality
May has 1 positive and 3 negative years (last 5 years shown)
0% return in May, -3% avg return in past 3 year May month.
10% return in 2026, -102% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 7% | -24% | 19% | 8% | 0% | – | – | – | – | – | – | – | 10% |
| 25 | -27% | -15% | -32% | -30% | 24% | -33% | 2% | -10% | 2% | 102% | -36% | -54% | -108% |
| 24 | -67% | 2% | -3% | -8% | -30% | 51% | -6% | -35% | -4% | -17% | -1% | -27% | -145% |
| 23 | -22% | -23% | -26% | 19% | -3% | -16% | -14% | -30% | -24% | 47% | 88% | -48% | -52% |
| 22 | -26% | 6% | -20% | -8% | -8% | 10% | 8% | -17% | -20% | -9% | -16% | -42% | -142% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metastatic breast, colorectal, hepatocellular, pancreatic, gastric, and other solid tumors; and NGC-Iri (PCS11T), an analog of an active metabolite of irinotecan, which is in preclinical trials to treat lung, pancreatic, ovarian, colorectal, gastric, cervical, and other cancers. The company also develops non-oncology drugs consisting of PCS499, an oral tablet of the deuterated analog of pentoxifylline that has completed a Phase 2b clinical trial for the treatment of primary glomerular diseases, including focal segmental glomerulosclerosis (FSGS), IgA, and membranous nephropathy, as well as ulcerative necrobiosis lipoidica; and PCS12852, a highly specific and potent 5HT4 agonist that has completed a Phase 2 clinical trial for the treatment of gastroparesis and constipation disorders. It has license agreements with Elion Oncology, Inc., Aposense, Ltd., Yuhan Corporation, and Sun Pharmaceuticals Industries Limited. Processa Pharmaceuticals, Inc. was founded in 2015 and is based in Vero Beach, Florida.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$7.12M
P/E ratio
—
52W high
$19.62
52W low
$1.76
Volume
37,828
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Processa Pharmaceuticals, Inc. share price today?
- Processa Pharmaceuticals, Inc. (PCSA) last traded around $2.65 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does PCSA have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for PCSA. Download the app for real-time alerts.
- How can I analyze Processa Pharmaceuticals, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.